{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:04:53Z","timestamp":1790089493532,"version":"4.0.1"},"reference-count":100,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Glioblastoma (GBM) is the most prevalent and aggressive malignant primary brain tumour, originating from glial cells known as astrocytes and accounting for over 50% of all central nervous system malignancies. Its aetiology is linked to various factors, including radiation exposure, genetic alterations, and viral influences, which trigger the uncontrolled growth and rapid infiltration of glial cells into surrounding brain tissues. Despite standard multidisciplinary management involving maximal safe surgical resection, radiotherapy, and temozolomide, the prognosis remains poor. The molecular landscape of GBM is characterised by profound dysregulation across highly conserved signalling networks, including the PI3K\/AKT\/mTOR, ERK\/MAPK, Wnt\/\u03b2-catenin, and Hippo pathways. These pathways are frequently hijacked by genetic and epigenetic alterations such as EGFR amplification and PTEN loss, which drive essential hallmarks of cancer like uncontrolled proliferation, angiogenesis, and apoptosis evasion. A defining feature of GBM is its extreme intra-tumoral heterogeneity and cellular plasticity, where tumour cells dynamically transition between distinct transcriptional states, including mesenchymal, astrocyte-like, and neural progenitor-like, to adapt to therapeutic pressures. This complexity is further exacerbated by microenvironmental factors. Clinical progress is severely hindered by the blood\u2013brain barrier (BBB), which restricts systemic agents from reaching invasive tumour margins. Targeted monotherapies, such as EGFR and mTOR inhibitors, have largely failed in clinical trials due to compensatory feedback loops and pathway redundancy. Consequently, the therapeutic paradigm is shifting toward rational combination therapies and novel immunotherapeutic platforms. Emerging strategies, such as bivalent CAR T-cell therapy targeting both EGFRvIII and IL-13R\u03b12, have shown early clinical promise in achieving tumour regression, highlighting a potential path toward precision medicine. This review synthesises current insights into signalling dysregulation and explores the future frontiers of multi-targeted therapeutic interventions in GBM.<\/jats:p>","DOI":"10.3390\/biology15191689","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:19:03Z","timestamp":1790086743000},"page":"1689","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disrupted Signalling Landscapes in Glioblastoma: Mechanistic Insights and Therapeutic Frontiers"],"prefix":"10.3390","volume":"15","author":[{"given":"Ammar Asif Ali","family":"Ansari","sequence":"first","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Haddad","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Assed","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Awaad","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"},{"name":"Imperial College London, London SW7 2AZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifa","family":"Badruddin","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afroditi","family":"Damou","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taslima Haque","family":"Shuwara","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marihah","family":"Rizwy","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Wehida","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2102-7339","authenticated-orcid":false,"given":"Ahmed","family":"Elbediwy","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"ref_1","unstructured":"Mesfin, F.B., and Al-Dhahir, M.A. (2025, December 21). Cancer, Brain Gliomas, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK441874\/."},{"key":"ref_2","unstructured":"National Cancer Institute (2025, December 21). Glioblastoma\u2014Unraveling the Threads: A Q&A with Drs. Mark Gilbert and Terri Armstrong of the NIH Neuro-Oncology Branch, Available online: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2017\/glioblastoma-research-making-progress."},{"key":"ref_3","unstructured":"Thakkar, J.P., Peruzzi, P.P., and Prabhu, V.C. (2025, December 23). Glioblastoma Multiforme. Available online: https:\/\/www.aans.org\/patients\/conditions-treatments\/glioblastoma-multiforme\/."},{"key":"ref_4","unstructured":"Brennan, C. (2025, December 23). What Is Astrocytoma, and How Is It Different from Glioblastoma?. Available online: https:\/\/www.mdanderson.org\/cancerwise\/what-is-astrocytoma--and-how-is-it-different-from-glioblastoma.h00-159694389.html."},{"key":"ref_5","unstructured":"American Cancer Society (2025, December 23). Glioblastoma. Available online: https:\/\/www.cancer.org\/cancer\/types\/glioblastoma.html."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Seker-Polat, F., Pinarbasi Degirmenci, N., Solaroglu, I., and Bagci-Onder, T. (2022). Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives. Cancers, 14.","DOI":"10.3390\/cancers14020443"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e233208","DOI":"10.1136\/bcr-2019-233208","article-title":"Subtle Neuropsychiatric Symptoms of Glioblastoma Multiforme Misdiagnosed as Depression","volume":"13","author":"Leo","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"105780","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma Multiforme (GBM): An Overview of Current Therapies and Mechanisms of Resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Triarico, S., Maurizi, P., Mastrangelo, S., Attin\u00e0, G., Capozza, M.A., and Ruggiero, A. (2019). Improving the Brain Delivery of Chemotherapeutic Drugs in Childhood Brain Tumors. Cancers, 11.","DOI":"10.3390\/cancers11060824"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sipos, D., Raposa, B.L., Freihat, O., Simon, M., Mekis, N., Cornacchione, P., and Kov\u00e1cs Glioblastoma, \u00c1. (2025). Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes. Cancers, 17.","DOI":"10.3390\/cancers17010146"},{"key":"ref_11","unstructured":"National Cancer Institute (2026, January 17). New Study Explores How Glioblastoma Cells Can Undergo Exploratory Adaptation to Survive and Cause Recurrence, Available online: https:\/\/ccr.cancer.gov\/neuro-oncology-branch\/how-glioblastoma-cells-can-adapt."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Duan, M., Cao, R., Yang, Y., Chen, X., Liu, L., Ren, B., Wang, L., and Goh, B.-C. (2024). Blood\u2013Brain Barrier Conquest in Glioblastoma Nanomedicine: Strategies, Clinical Advances, and Emerging Challenges. Cancers, 16.","DOI":"10.20944\/preprints202409.0186.v1"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the Crossroads: Current Understanding and Future Therapeutic Horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114204","DOI":"10.1016\/j.biopha.2022.114204","article-title":"Progress in Targeting PTEN\/PI3K\/Akt Axis in Glioblastoma Therapy: Revisiting Molecular Interactions","volume":"158","author":"Hashemi","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/labinvest.2015.140","article-title":"WNT Signaling in Glioblastoma and Therapeutic Opportunities","volume":"96","author":"Lee","year":"2015","journal-title":"Lab. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"103452","DOI":"10.1016\/j.ebiom.2021.103452","article-title":"Increased Expression of Yes-Associated Protein\/YAP and Transcriptional Coactivator with PDZ-Binding Motif\/TAZ Activates Intestinal Fibroblasts to Promote Intestinal Obstruction in Crohn\u2019s Disease","volume":"69","author":"Ou","year":"2021","journal-title":"eBioMedicine"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wu, H., Wei, M., Li, Y., Ma, Q., and Zhang, H. (2022). Research Progress on the Regulation Mechanism of Key Signal Pathways Affecting the Prognosis of Glioma. Front. Mol. Neurosci., 15.","DOI":"10.3389\/fnmol.2022.910543"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33440","DOI":"10.18632\/oncotarget.7961","article-title":"PI3K\/Akt\/mTOR Signaling Pathway and Targeted Therapy for Glioblastoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., and Saoud, K. (2018). The P53 Pathway in Glioblastoma. Cancers, 10.","DOI":"10.3390\/cancers10090297"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11060-026-05428-3","article-title":"Disrupting Akt-Wnt\/\u03b2-Catenin Signaling Suppresses Glioblastoma Stem Cell Growth and Tumor Progression in Immunocompetent Mice","volume":"177","author":"Sarkar","year":"2026","journal-title":"J. Neuro-Oncol."},{"key":"ref_21","first-page":"1997","article-title":"ERK\/MAPK Signalling Pathway and Tumorigenesis (Review)","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7968","DOI":"10.1038\/s41467-026-74124-7","article-title":"Glioma-Intrinsic MAPK\/ERK Signaling Promotes Immunotherapy Efficacy through T Cell Infiltration and Interferon Responses","volume":"17","author":"Kim","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jiang, M., Zhang, Y., Li, P., Jian, J., Zhao, C., and Wen, G. (2022). Mitogen-Activated Protein Kinase and Substrate Identification in Plant Growth and Development. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052744"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","article-title":"The Ras\/Raf\/MAPK Pathway","volume":"1","author":"Molina","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.bbamcr.2010.12.012","article-title":"The MAPK Cascades: Signaling Components, Nuclear Roles and Mechanisms of Nuclear Translocation","volume":"1813","author":"Plotnikov","year":"2011","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ansari, A., Szczesnowska, A., Haddad, N., Elbediwy, A., and Wehida, N. (2025). The Role of Non-Coding RNAs in the Regulation of Oncogenic Pathways in Breast and Gynaecological Cancers. Non-Coding RNA, 11.","DOI":"10.3390\/ncrna11040061"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt Signal Transduction for Cancer Therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2016.03.004","article-title":"New Insights on PI3K\/AKT Pathway Alterations and Clinical Outcomes in Breast Cancer","volume":"45","author":"Yang","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/\u03b2-Catenin Signaling: Components, Mechanisms, and Diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Haddad, N., Gamaethige, S.M., Wehida, N., and Elbediwy, A. (2024). Drug Repurposing: Exploring Potential Anti-Cancer Strategies by Targeting Cancer Signalling Pathways. Biology, 13.","DOI":"10.3390\/biology13060386"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Xiao, Y., and Dong, J. (2021). The Hippo Signaling Pathway in Cancer: A Cell Cycle Perspective. Cancers, 13.","DOI":"10.3390\/cancers13246214"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The Hippo Pathway: Biology and Pathophysiology","volume":"88","author":"Ma","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","article-title":"RNA Splicing Dysregulation and the Hallmarks of Cancer","volume":"23","author":"Bradley","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"111184","DOI":"10.1016\/j.brainresbull.2024.111184","article-title":"Deciphering Glioblastoma Pathogenesis: Insights from Mitophagy Dysregulation and SNX7 as a Therapeutic Target","volume":"220","author":"Zhang","year":"2024","journal-title":"Brain Res. Bull."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12032-025-02905-z","article-title":"Epigenetic Dysregulation in Cancer: Mechanisms, Diagnostic Biomarkers and Therapeutic Strategies","volume":"42","author":"Imran","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Masliantsev, K., Karayan-Tapon, L., and Guichet, P.-O. (2021). Hippo Signaling Pathway in Gliomas. Cells, 10.","DOI":"10.3390\/cells10010184"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"36255","DOI":"10.18632\/oncotarget.9199","article-title":"The Hippo Transducer TAZ Promotes Cell Proliferation and Tumor Formation of Glioblastoma Cells through EGFR Pathway","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kim, E.H., Sohn, B.H., Eun, Y.-G., Lee, D.J., Yim, S.Y., Kang, S.-G., and Lee, J.-S. (2020). Silence of Hippo Pathway Associates with Pro-Tumoral Immunosuppression: Potential Therapeutic Target of Glioblastomas. Cells, 9.","DOI":"10.3390\/cells9081761"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.21037\/jtd.2019.01.16","article-title":"Hippo Pathway as Another Oncogenic Mediator to Promote Immune Evasion by PD-L1 Signaling","volume":"11","author":"Hong","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/s12276-025-01551-9","article-title":"The Multifaceted Role of YAP in the Tumor Microenvironment and Its Therapeutic Implications in Cancer","volume":"57","author":"Kim","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory Mechanisms of PD-1\/PD-L1 in Cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","article-title":"Sequestration of T Cells in Bone Marrow in the Setting of Glioblastoma and Other Intracranial Tumors","volume":"24","author":"Chongsathidkiet","year":"2018","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102597","DOI":"10.1016\/j.stemcr.2025.102597","article-title":"Modeling Glioma Intratumoral Heterogeneity with Primary Human Neural Stem and Progenitor Cells","volume":"20","author":"Liu","year":"2025","journal-title":"Stem Cell Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cell.2023.12.013","article-title":"Glioblastoma Evolution and Heterogeneity from a 3D Whole-Tumor Perspective","volume":"187","author":"Mathur","year":"2024","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/neuonc\/noab269","article-title":"Cancer Cell Heterogeneity and Plasticity: A Paradigm Shift in Glioblastoma","volume":"24","author":"Yabo","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"112235","DOI":"10.1016\/j.celrep.2023.112235","article-title":"Single-Cell Heterogeneity of EGFR and CDK4 Co-Amplification Is Linked to Immune Infiltration in Glioblastoma","volume":"42","author":"Walentynowicz","year":"2023","journal-title":"Cell Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer Stem Cells: Advances in Knowledge and Implications for Cancer Therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1002\/1878-0261.13706","article-title":"Unravelling the Mosaic: Epigenetic Diversity in Glioblastoma","volume":"18","author":"Lucchini","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","article-title":"Glioblastoma Heterogeneity at Single Cell Resolution","volume":"42","author":"Eisenbarth","year":"2023","journal-title":"Oncogene"},{"key":"ref_52","first-page":"srep07979","article-title":"The Evidence of Glioblastoma Heterogeneity","volume":"5","author":"Soeda","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Berezovsky, A., Nuga, O., Datta, I., Bergman, K., Sabedot, T., Gurdziel, K., Irtenkauf, S., Hasselbach, L., Meng, Y., and Mueller, C. (2025). Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0315171"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.neuroscience.2024.09.022","article-title":"Contemporary Strategies in Glioblastoma Therapy: Recent Developments and Innovations","volume":"560","author":"Khan","year":"2024","journal-title":"Neuroscience"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cpt.2023.11.006","article-title":"Intraoperative Glioblastoma Surgery-Current Challenges and Clinical Trials: An Update","volume":"2","author":"Patel","year":"2024","journal-title":"Cancer Pathog. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.neurol.2023.03.013","article-title":"Overcoming the Blood Brain Barrier in Glioblastoma: Status and Future Perspective","volume":"179","author":"Ahmed","year":"2023","journal-title":"Rev. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Jain, K.K. (2018). A Critical Overview of Targeted Therapies for Glioblastoma. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00419"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-025-02267-0","article-title":"Glioblastoma Multiforme: Insights into Pathogenesis, Key Signaling Pathways, and Therapeutic Strategies","volume":"24","author":"Pouyan","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic Advances of Targeting Receptor Tyrosine Kinases in Cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41419-025-07771-1","article-title":"EGFRvIII-Positive Glioblastoma Contributes to Immune Escape and Malignant Progression via the C-Fos-MDK-LRP1 Axis","volume":"16","author":"Yuan","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41392-023-01637-8","article-title":"From Signalling Pathways to Targeted Therapies: Unravelling Glioblastoma\u2019s Secrets and Harnessing Two Decades of Progress","volume":"8","author":"Dewdney","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"viii14","DOI":"10.1093\/neuonc\/nou222","article-title":"Challenges to Targeting Epidermal Growth Factor Receptor in Glioblastoma: Escape Mechanisms and Combinatorial Treatment Strategies","volume":"16","author":"Roth","year":"2014","journal-title":"Neuro-Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Padfield, E., Ellis, H.P., and Kurian, K.M. (2015). Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma. Front. Oncol., 5.","DOI":"10.3389\/fonc.2015.00005"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"118237","DOI":"10.1016\/j.biopha.2025.118237","article-title":"The mTOR Pathway in Gliomas: From Molecular Insights to Targeted Therapies","volume":"189","author":"Pournajaf","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","article-title":"Suppression of Feedback Loops Mediated by PI3K\/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance","volume":"13","author":"Rozengurt","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nature17963","article-title":"Overcoming mTOR Resistance Mutations with a New-Generation mTOR Inhibitor","volume":"534","author":"Okaniwa","year":"2016","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"vdac185","DOI":"10.1093\/noajnl\/vdac185","article-title":"Tandem Chimeric Antigen Receptor (CAR) T Cells Targeting EGFRvIII and IL-13R\u03b12 Are Effective against Heterogeneous Glioblastoma","volume":"5","author":"Schmidts","year":"2022","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.2147\/IJGM.S418837","article-title":"Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma","volume":"16","author":"Liang","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"ref_69","unstructured":"Second Affiliated Hospital, School of Medicine, Zhejiang University (2025, December 23). Pilot Study of B7-H3 CAR-T in Treating Patients with Recurrent and Refractory Glioblastoma. ClinicalTrials.gov Identifier: NCT04385173, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04385173."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14712598.2020.1727436","article-title":"CAR T Cells and Checkpoint Inhibition for the Treatment of Glioblastoma","volume":"20","author":"Shen","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Cook, D.R., Boesteanu, A.C., Yin, Y., Reid, R., Roccograndi, L., Dahmane, N., Martinez-Lage, M., O\u2019Rourke, D.M., June, C.H., and Johnson, L.A. (2025). Checkpoint Antibody Receptor Modified ARMed CAR T Circumvents the Suppressive Immunome in GBM. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1579925"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem Cells, Cancer, and Cancer Stem Cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ou, A., Yung, W.K.A., and Majd, N. (2020). Molecular Mechanisms of Treatment Resistance in Glioblastoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010351"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/curroncol31070296","article-title":"Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme\u2014A Literature Review and Clinical Outcomes","volume":"31","author":"Nafalska","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12672-025-02567-3","article-title":"Glioblastoma Multiforme: An Updated Overview of Temozolomide Resistance Mechanisms and Strategies to Overcome Resistance","volume":"16","author":"Pu","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Georgescu, M.-M. (2021). Multi-Platform Classification of IDH-Wild-Type Glioblastoma Based on ERK\/MAPK Pathway: Diagnostic, Prognostic and Therapeutic Implications. Cancers, 13.","DOI":"10.3390\/cancers13184532"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11060-024-04930-w","article-title":"It\u2019s All Downstream from Here: RTK\/Raf\/MEK\/ERK Pathway Resistance Mechanisms in Glioblastoma","volume":"172","author":"Yakubov","year":"2025","journal-title":"J. Neuro-Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Tang, J., Karbhari, N., and Campian, J.L. (2025). Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions. Cells, 14.","DOI":"10.20944\/preprints202502.1189.v1"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9597","DOI":"10.2147\/IJN.S531451","article-title":"Advances and Challenges in Nano-Delivery Systems for Glioblastoma Treatment: A Comprehensive Review","volume":"20","author":"Wang","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering Precision Nanoparticles for Drug Delivery","volume":"20","author":"Mitchell","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM Elicited by Injection of Liposomes Is Involved in the Enhanced Blood Clearance of a Subsequent Dose of PEGylated Liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_83","first-page":"2068","article-title":"PLGA Based Nanomaterials in Drug Delivery for Cancer Treatment: Innovations and Emerging Applications","volume":"3","author":"Morker","year":"2025","journal-title":"Int. J. Pharm. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"118733","DOI":"10.1016\/j.ijpharm.2019.118733","article-title":"Doxorubicin-Loaded PLGA Nanoparticles for the Chemotherapy of Glioblastoma: Towards the Pharmaceutical Development","volume":"572","author":"Maksimenko","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1021\/cr068445e","article-title":"Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological Applications","volume":"108","author":"Laurent","year":"2008","journal-title":"Chem. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.tibtech.2011.03.001","article-title":"Cancer Theranostics: The Rise of Targeted Magnetic Nanoparticles","volume":"29","author":"Cole","year":"2011","journal-title":"Trends Biotechnol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/anie.200602866","article-title":"Magnetic Nanoparticles: Synthesis, Protection, Functionalization, and Application","volume":"46","author":"Lu","year":"2007","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0304-8853(00)01239-7","article-title":"Presentation of a New Magnetic Field Therapy System for the Treatment of Human Solid Tumors with Magnetic Fluid Hyperthermia","volume":"225","author":"Jordan","year":"2001","journal-title":"J. Magn. Magn. Mater."},{"key":"ref_89","first-page":"317","article-title":"Efficacy and Safety of Intratumoral Thermotherapy Using Magnetic Iron-Oxide Nanoparticles Combined with External Beam Radiotherapy on Patients with Recurrent Glioblastoma Multiforme","volume":"103","author":"Ulrich","year":"2010","journal-title":"J. Neuro-Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"N309","DOI":"10.1088\/0031-9155\/49\/18\/N03","article-title":"The Use of Gold Nanoparticles to Enhance Radiotherapy in Mice","volume":"49","author":"Hainfeld","year":"2004","journal-title":"Phys. Med. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1039\/c2nr31227a","article-title":"Physical Basis and Biological Mechanisms of Gold Nanoparticle Radiosensitization","volume":"4","author":"Butterworth","year":"2012","journal-title":"Nanoscale"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cmmi.1551","article-title":"Nanoparticle Contrast Agents for Computed Tomography: A Focus on Micelles","volume":"9","author":"Cormode","year":"2014","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.prro.2013.01.067","article-title":"Selective Targeting of Brain Tumors With Nanoparticle-Induced Radiosensitization and Contrast Enhancement","volume":"3","author":"Sun","year":"2013","journal-title":"Pr. Radiat. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11060-015-1958-z","article-title":"A Phase II Study of Bevacizumab and Erlotinib after Radiation and Temozolomide in MGMT Unmethylated GBM Patients","volume":"126","author":"Raizer","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Ezzati, S., Salib, S., Balasubramaniam, M., and Aboud, O. (2024). Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042316"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"530","DOI":"10.18632\/oncotarget.188","article-title":"Targeting the PI3K\/Akt\/mTOR Pathway\u2014Beyond Rapalogs","volume":"1","author":"Markman","year":"2010","journal-title":"Oncotarget"},{"key":"ref_97","first-page":"666","article-title":"A Randomized Phase II Study of Everolimus in Combination with Chemoradiation in Newly Diagnosed Glioblastoma: Results of NRG Oncology RTOG 0913","volume":"20","author":"Prakash","year":"2017","journal-title":"Neuro-Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00280-011-1773-y","article-title":"Ridaforolimus for Patients with Progressive or Recurrent Malignant Glioma: A Perisurgical, Sequential, Ascending-Dose Trial","volume":"69","author":"Reardon","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","article-title":"Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)","volume":"22","author":"Wick","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_100","unstructured":"University of Pennsylvania (2026, August 05). CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM. ClinicalTrials.gov Identifier: NCT05168423, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05168423."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/15\/19\/1689\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:30:53Z","timestamp":1790087453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/15\/19\/1689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":100,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["biology15191689"],"URL":"https:\/\/doi.org\/10.3390\/biology15191689","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]}}}